European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Retrieved on: 2022-12-15 16:59:04

Tags for this article:

Click the tags to see associated articles and topics

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine. View article details on hiswai:

Excerpt

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is ...

Article found on: www.labiotech.eu